Clinical Trial Update: FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial (FIRST-NEC, GFPC 01-2022) is evaluating durvalumab in combination with etoposide and platinum for Large Cell Neuroendocrine Carcinoma o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Large Cell Neuroendocrine Carcinoma of the Lung

Drugs mentioned

• Durvalumab (durvalumab)
• Etoposide (Etoposide)
• Platinum-based chemotherapy (platinum-based chemotherapy)

Snippet

Sponsor: Centre Leon Berard | Conditions: Large Cell Neuroendocrine Carcinoma of the Lung | Phase 2 | Status: RECRUITING